Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer
出版年份 2011 全文链接
标题
Perineural Invasion and Lymph Node Involvement as Indicators of Surgical Outcome and Pattern of Recurrence in the Setting of Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Pancreatic Cancer
作者
关键词
-
出版物
ANNALS OF SURGERY
Volume 255, Issue 1, Pages 95-102
出版商
Ovid Technologies (Wolters Kluwer Health)
发表日期
2011-11-26
DOI
10.1097/sla.0b013e31823d813c
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Ep-CAM is a significant prognostic factor in pancreatic cancer patients by suppressing cell activity
- (2011) H Akita et al. ONCOGENE
- Serum CA19–9 Alterations During Preoperative Gemcitabine-Based Chemoradiation Therapy for Resectable Invasive Ductal Carcinoma of the Pancreas as an Indicator for Therapeutic Selection and Survival
- (2010) Hidenori Takahashi et al. ANNALS OF SURGERY
- Serum CA 19-9 as a Marker of Resectability and Survival in Patients with Potentially Resectable Pancreatic Cancer Treated with Neoadjuvant Chemoradiation
- (2010) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Adjuvant Interferon-based Chemoradiation Followed By Gemcitabine for Resected Pancreatic Adenocarcinoma: A Single-Institution Phase II Study
- (2009) David C. Linehan et al. ANNALS OF SURGERY
- Feasibility and Efficacy of Combination Therapy With Preoperative Full-Dose Gemcitabine, Concurrent Three-Dimensional Conformal Radiation, Surgery, and Postoperative Liver Perfusion Chemotherapy for T3-Pancreatic Cancer
- (2009) Hiroaki Ohigashi et al. ANNALS OF SURGERY
- Long-Term Survival After Multidisciplinary Management of Resected Pancreatic Adenocarcinoma
- (2009) Matthew H. G. Katz et al. ANNALS OF SURGICAL ONCOLOGY
- Cancer Statistics, 2009
- (2009) A. Jemal et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Single Nucleotide Polymorphisms of Gemcitabine Metabolic Genes and Pancreatic Cancer Survival and Drug Toxicity
- (2009) T. Okazaki et al. CLINICAL CANCER RESEARCH
- Human Equilibrative Nucleoside Transporter 1 and Human Concentrative Nucleoside Transporter 3 Predict Survival after Adjuvant Gemcitabine Therapy in Resected Pancreatic Adenocarcinoma
- (2009) R. Marechal et al. CLINICAL CANCER RESEARCH
- Reg IV Regulates Normal Intestinal and Colorectal Cancer Cell Susceptibility to Radiation-Induced Apoptosis
- (2009) Kumar S. Bishnupuri et al. GASTROENTEROLOGY
- DPC4 Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer
- (2009) Christine A. Iacobuzio-Donahue et al. JOURNAL OF CLINICAL ONCOLOGY
- Serum REG4 Level Is a Predictive Biomarker for the Response to Preoperative Chemoradiotherapy in Patients With Pancreatic Cancer
- (2009) Hidetoshi Eguchi et al. PANCREAS
- Histopathological Response to Preoperative Chemoradiation for Resectable Pancreatic Adenocarcinoma
- (2008) Romuald Le Scodan et al. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
- Neoadjuvant and adjuvant strategies for pancreatic cancer
- (2008) P. Ghaneh et al. EJSO
- Preoperative chemoradiation in adenocarcinoma of the pancreas. A single centre experience advocating a new treatment strategy
- (2008) H. Golcher et al. EJSO
- Human Equilibrative Nucleoside Transporter 1 Levels Predict Response to Gemcitabine in Patients With Pancreatic Cancer
- (2008) James J. Farrell et al. GASTROENTEROLOGY
- Full-Dose Gemcitabine With Concurrent Radiation Therapy in Patients With Nonmetastatic Pancreatic Cancer: A Multicenter Phase II Trial
- (2008) William Small et al. JOURNAL OF CLINICAL ONCOLOGY
- Preoperative Gemcitabine-Based Chemoradiation for Patients With Resectable Adenocarcinoma of the Pancreatic Head
- (2008) Douglas B. Evans et al. JOURNAL OF CLINICAL ONCOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started